{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:30:53Z","timestamp":1793413853171,"version":"4.5.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jid.2026.05.023","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:28:24Z","timestamp":1783456104000},"page":"2984-2998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["History and future of RNA medicines"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3412-7512","authenticated-orcid":false,"given":"Alain","family":"Hovnanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1534-9689","authenticated-orcid":false,"given":"Guillaume","family":"Mondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-2769","authenticated-orcid":false,"given":"Matthias","family":"Titeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2026.05.023_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.05.023_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119673","article-title":"Current trends in polymer microneedle for transdermal drug delivery","volume":"587","author":"Ahmed Saeed Al-Japairai","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jid.2026.05.023_bib4","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/jama.2024.14637","article-title":"N-of-1 studies in an era of precision medicine","volume":"332","author":"Augustine","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2026.05.023_bib5","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.3390\/ijms23168875","article-title":"Transcript-targeted therapy based on RNA interference and antisense oligonucleotides: current applications and novel molecular targets","volume":"23","author":"Barresi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2026.05.023_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jid.2026.05.023_bib7","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1093\/nar\/23.21.4239","article-title":"Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent","volume":"23","author":"Benimetskaya","year":"1995","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1021\/acs.bioconjchem.8b00761","article-title":"Bioconjugated oligonucleotides: recent developments and therapeutic applications","volume":"30","author":"Benizri","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.jid.2026.05.023_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jid.2026.05.023_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/nmt-2018-0037","article-title":"Inotersen (transthyretin \u2013 specific antisense oligonucleotide) for treatment of transthyretin amyloidosis","volume":"9","author":"Benson","year":"2019","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.jid.2026.05.023_bib11","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1073\/pnas.74.8.3171","article-title":"Spliced segments at the 5' terminus of adenovirus 2 late mRNA","volume":"74","author":"Berget","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2026.05.023_bib12","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/nar\/gky1239","article-title":"Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo","volume":"47","author":"Biscans","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib13","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/jid.2008.85","article-title":"T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis","volume":"128","author":"Blauvelt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib14","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1093\/nar\/24.23.4660","article-title":"Watson-Crick base-pairing properties of bicyclo-DNA","volume":"24","author":"Bolli","year":"1996","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib15","doi-asserted-by":"crossref","first-page":"22046","DOI":"10.1021\/acsnano.3c08644","article-title":"Lipid nanoparticle-mediated hit-and-run approaches yield efficient and safe in situ gene editing in human skin","volume":"17","author":"Bolsoni","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jid.2026.05.023_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jid.2020.08.018","article-title":"QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: a preclinical study","volume":"141","author":"Bornert","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib17","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/mt.2016.92","article-title":"Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy","volume":"24","author":"Bornert","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/exd.13141","article-title":"RNA-based therapies for genodermatoses","volume":"26","author":"Bornert","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib138","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1038\/mtna.2016.87","article-title":"Antisense oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa","volume":"5","author":"Bremer","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jid.2026.05.023_bib19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/190576a0","article-title":"An unstable intermediate carrying information from genes to ribosomes for protein synthesis","volume":"190","author":"Brenner","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.jid.2026.05.023_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0092-8674(92)90519-I","article-title":"The product of the mouse Xist gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus","volume":"71","author":"Brockdorff","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.jid.2026.05.023_bib21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0092-8674(92)90520-M","article-title":"The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus","volume":"71","author":"Brown","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.jid.2026.05.023_bib22","doi-asserted-by":"crossref","first-page":"7945","DOI":"10.1038\/s41598-019-44388-9","article-title":"Aptamer-based targeted delivery of a G-quadruplex ligand in cervical cancer cells","volume":"9","author":"Carvalho","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2026.05.023_bib23","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1093\/nar\/gkaa164","article-title":"Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice","volume":"48","author":"Chappell","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0092-8674(77)90180-5","article-title":"An amazing sequence arrangement at the 5' ends of adenovirus 2 messenger RNA","volume":"12","author":"Chow","year":"1977","journal-title":"Cell"},{"key":"10.1016\/j.jid.2026.05.023_bib25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/bjd.17840","article-title":"MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts","volume":"181","author":"Condorelli","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2026.05.023_bib28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/nat.2016.0650","article-title":"The effects of 2'-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib29","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jid.2021.12.026","article-title":"FPR2 DNA aptamers for targeted therapy of wound repair","volume":"142","author":"de Arriba","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib30","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jdermsci.2019.11.003","article-title":"Integrated microRNA\/mRNA expression profiling of the skin of psoriasis patients","volume":"97","author":"Deli\u0107","year":"2020","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jid.2026.05.023_bib32","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","article-title":"Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides","volume":"90","author":"Dominski","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2026.05.023_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/nat.2022.0004","article-title":"Delivery of RNA therapeutics: the great endosomal escape","volume":"32","author":"Dowdy","year":"2022","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2012.04.005","article-title":"Roles for microRNAs in conferring robustness to biological processes","volume":"149","author":"Ebert","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jid.2026.05.023_bib35","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.jid.2026.05.023_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1166","article-title":"The druggable genome and support for target identification and validation in drug development","volume":"9","author":"Finan","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2026.05.023_bib37","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2026.05.023_bib38","doi-asserted-by":"crossref","first-page":"9193","DOI":"10.1093\/nar\/17.22.9193","article-title":"RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds","volume":"17","author":"Furdon","year":"1989","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib39","article-title":"A placebo-controlled study of PF-06473871 (anti-connective tissue growth factor antisense oligonucleotide) in reducing hypertrophic skin scarring","volume":"6","author":"Gale","year":"2018","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.jid.2026.05.023_bib40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/wrr.12660","article-title":"A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds","volume":"26","author":"Gallant-Behm","year":"2018","journal-title":"Wound Repair Regeneration"},{"key":"10.1016\/j.jid.2026.05.023_bib41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4137\/OED.S4878","article-title":"Bevasiranib for the treatment of wet, age-related macular degeneration","volume":"2","author":"Garba","year":"2010","journal-title":"Ophthalmol Eye Dis"},{"key":"10.1016\/j.jid.2026.05.023_bib42","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.05.023_bib43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jid.2026.05.023_bib44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15252\/emmm.201607199","article-title":"Delivery is key: lessons learnt from developing splice-switching antisense therapies","volume":"9","author":"Godfrey","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jid.2026.05.023_bib45","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1038\/sj.jid.5700435","article-title":"Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients","volume":"126","author":"Goto","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib46","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.3765","article-title":"Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers","volume":"21","author":"Goyenvalle","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2026.05.023_bib47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JND-160146","article-title":"Therapeutic Potential of tricyclo-DNA antisense oligonucleotides","volume":"3","author":"Goyenvalle","year":"2016","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.jid.2026.05.023_bib48","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/190581a0","article-title":"Unstable ribonucleic acid revealed by pulse labelling of Escherichia coli","volume":"190","author":"Gros","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.jid.2026.05.023_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102036","article-title":"The decoy oligodeoxynucleotide against HIF-1alpha and STAT5 ameliorates atopic dermatitis-like mouse model","volume":"34","author":"Gwon","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jid.2026.05.023_bib50","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-Small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib51","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","article-title":"Mipomersen sodium: first global approval","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jid.2026.05.023_bib52","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.3390\/ijms21207705","article-title":"Nonsequential splicing events alter antisense-mediated exon skipping outcome in COL7A1","volume":"21","author":"Ham","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2026.05.023_bib53","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jid.2026.05.023_bib54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrg3863","article-title":"RNA-mediated epigenetic regulation of gene expression","volume":"16","author":"Holoch","year":"2015","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jid.2026.05.023_bib55","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.7150\/thno.54217","article-title":"Co-delivery of siPTPN13 and siNOX4 via (myo)fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy","volume":"11","author":"Hou","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jid.2026.05.023_bib56","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/cimb43030090","article-title":"Renadirsen, a novel 2'OMeRNA\/ENA((R)) chimera antisense oligonucleotide, induces robust Exon 45 skipping for dystrophin in vivo","volume":"43","author":"Ito","year":"2021","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.jid.2026.05.023_bib57","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/nass\/nrn254","article-title":"Tc-DNA modified siRNA","volume":"52","author":"Ittig","year":"2008","journal-title":"Nucleic Acids Symp (Oxf)"},{"key":"10.1016\/j.jid.2026.05.023_bib58","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2026.05.023_bib59","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.05.023_bib60","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/19768354.2025.2548253","article-title":"The RNA revolution in medicine: from gene regulation to clinical therapeutics","volume":"29","author":"Jeong","year":"2025","journal-title":"Anim Cells Syst"},{"key":"10.1016\/j.jid.2026.05.023_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114872","article-title":"Development of nucleic acid medicines based on chemical technology","volume":"199","author":"Kawamoto","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jid.2026.05.023_bib62","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jid.2026.05.023_bib63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.29245\/2767-5092\/2023\/1.1168","article-title":"The dawning of a new enterprise: RNA therapeutics for the skin","volume":"5","author":"Kieser","year":"2023","journal-title":"J Dermatol Skin Sci"},{"key":"10.1016\/j.jid.2026.05.023_bib64","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70207","article-title":"A first-in-human Phase 1 study to evaluate the safety and tolerability of LEM-S401, a novel siRNA-DegradaBALL drug targeting CTGF in healthy adults","volume":"18","author":"Kim","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jid.2026.05.023_bib65","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.05.023_bib66","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","article-title":"A framework for individualized splice-switching oligonucleotide therapy","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jid.2026.05.023_bib67","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41586-024-07266-7","article-title":"Interim analyses of a first-in-human phase 1\/2 mRNA trial for propionic acidaemia","volume":"628","author":"Koeberl","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jid.2026.05.023_bib68","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr465","article-title":"A novel screening system improves genetic correction by internal exon replacement","volume":"39","author":"Koller","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis","volume":"28","author":"Korben","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2026.05.023_bib70","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature04303","article-title":"Silencing of microRNAs in vivo with 'antagomirs'","volume":"438","author":"Kr\u00fctzfeldt","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jid.2026.05.023_bib71","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/S0960-894X(98)00366-7","article-title":"The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-LNA","volume":"8","author":"Kumar","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jid.2026.05.023_bib72","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1046\/j.1432-1033.2003.03555.x","article-title":"Antisense technologies. Improvement through novel chemical modifications","volume":"270","author":"Kurreck","year":"2003","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.jid.2026.05.023_bib73","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.jid.2026.05.023_bib74","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2009.273","article-title":"First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder","volume":"18","author":"Leachman","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib75","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jid.2017.07.851","article-title":"RNA aptamer delivery through intact human skin","volume":"138","author":"Lenn","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib76","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70076","article-title":"Imetelstat, a novel, first-in-class telomerase inhibitor: mechanism of action, clinical, and translational science","volume":"17","author":"Lennox","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jid.2026.05.023_bib77","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ymthe.2018.04.021","article-title":"Topical lyophilized Targeted Lipid Nanoparticles in the Restoration of Skin Barrier Function following Burn Wound","volume":"26","author":"Li","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib78","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib79","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.3390\/ijms24054341","article-title":"COL7A1 editing via RNA trans-splicing in RDEB-derived skin equivalents","volume":"24","author":"Liemberger","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2026.05.023_bib80","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3390\/ijms23031732","article-title":"5'RNA trans-splicing repair of COL7A1 mutant transcripts in epidermolysis bullosa","volume":"23","author":"Mayr","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2026.05.023_bib81","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jid.2026.05.023_bib82","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.05.023_bib83","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1081\/NCN-120023082","article-title":"2'-O,4'-C-ethylene-bridged nucleic acid (ENA) for effective antisense formation","volume":"22","author":"Morita","year":"2003","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.jid.2026.05.023_bib84","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1093\/nar\/gks273","article-title":"TricycloDNA-modified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry","volume":"40","author":"Murray","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib85","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1261\/rna.058909.116","article-title":"An intermolecular G-quadruplex as the basis for GTP recognition in the class V-GTP aptamer","volume":"22","author":"Nasiri","year":"2016","journal-title":"RNA"},{"key":"10.1016\/j.jid.2026.05.023_bib86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2026.05.023_bib87","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0959-440X(99)80047-5","article-title":"Peptide nucleic acids as therapeutic agents","volume":"9","author":"Nielsen","year":"1999","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.jid.2026.05.023_bib88","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41576-024-00806-x","article-title":"The therapeutic potential of circular RNAs","volume":"26","author":"O'Leary","year":"2025","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jid.2026.05.023_bib89","first-page":"6045","article-title":"Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates","volume":"47","author":"\u00d8stergaard","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjd.17075","article-title":"An ex vivo RNA trans-splicing strategy to correct human generalized severe epidermolysis bullosa simplex","volume":"180","author":"Peking","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib91","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/jid.2012.11","article-title":"siRNA-mediated allele-specific inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa","volume":"132","author":"Pendaries","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib92","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2401781121","article-title":"Splice modulation strategy applied to deep intronic variants in COL7A1 causing recessive dystrophic epidermolysis bullosa","volume":"121","author":"Pironon","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2026.05.023_bib93","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib94","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1093\/nar\/gkz354","article-title":"Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle","volume":"47","author":"Prakash","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib95","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.05.023_bib96","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2026.05.023_bib97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/nar\/gkab1199","article-title":"Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides","volume":"50","author":"Relizani","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib98","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/nar\/gkf412","article-title":"Antisense properties of tricyclo-DNA","volume":"30","author":"Renneberg","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib99","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","article-title":"Viltolarsen for the treatment of Duchenne muscular dystrophy","volume":"55","author":"Roshmi","year":"2019","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.jid.2026.05.023_bib100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jid.2026.05.023_bib101","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/cells12060908","article-title":"Investigating the impact of delivery routes for exon skipping therapies in the CNS of DMD mouse models","volume":"12","author":"Saoudi","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jid.2026.05.023_bib102","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 trial of an RNA interference therapy for acute intermittent porphyria","volume":"380","author":"Sardh","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.05.023_bib103","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2119\/molmed.2015.00210","article-title":"Novel targeted therapy for precursor B cell acute lymphoblastic leukemia: anti-CD22 antibody-MXD3 antisense oligonucleotide conjugate","volume":"22","author":"Satake","year":"2016","journal-title":"Mol Med"},{"key":"10.1016\/j.jid.2026.05.023_bib104","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib105","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(25)00513-6","article-title":"Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series","volume":"405","author":"Shneider","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2026.05.023_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115198","article-title":"Nanotechnology strategies to address challenges in topical and cellular delivery of siRNAs in skin disease therapy","volume":"207","author":"Silvestrini","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jid.2026.05.023_bib107","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010818-021050","article-title":"Therapeutic oligonucleotides: state of the art","volume":"59","author":"Smith","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jid.2026.05.023_bib108","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jid.2026.05.023_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","article-title":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","volume":"237","author":"Sugo","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.jid.2026.05.023_bib110","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/156802607780487740","article-title":"Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity","volume":"7","author":"Summerton","year":"2007","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jid.2026.05.023_bib111","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41591-020-0787-6","article-title":"STAR particles for enhanced topical drug and vaccine delivery","volume":"26","author":"Tadros","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2026.05.023_bib112","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Tang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2026.05.023_bib113","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.ymthe.2022.04.019","article-title":"RNAi-based modulation of IFN-gamma signaling in skin","volume":"30","author":"Tang","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212284","article-title":"Recent advances and prospects in RNA drug development","volume":"25","author":"Tani","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2026.05.023_bib115","doi-asserted-by":"crossref","first-page":"12388","DOI":"10.1093\/nar\/gkx960","article-title":"Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes","volume":"45","author":"Tanowitz","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2026.05.023_bib116","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.05.023_bib117","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1515\/mr-2023-0062","article-title":"Assembling the RNA therapeutics toolbox","volume":"4","author":"Teng","year":"2024","journal-title":"Med Rev (2021)"},{"key":"10.1016\/j.jid.2026.05.023_bib118","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1046\/j.1523-1747.1998.00397.x","article-title":"Compound heterozygosity for a recessive glycine substitution and a splice site mutation in the COL7A1 gene causes an unusually mild form of localized recessive dystrophic epidermolysis bullosa","volume":"111","author":"Terracina","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib119","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/gt.2016.57","article-title":"Construction and validation of an RNA trans-splicing molecule suitable to repair a large number of COL7A1 mutations","volume":"23","author":"Tockner","year":"2016","journal-title":"Gene Ther"},{"key":"10.1016\/j.jid.2026.05.023_bib120","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jid.2026.05.023_bib121","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jid.2016.07.029","article-title":"Targeted exon skipping restores Type VII collagen expression and anchoring fibril formation in an in vivo RDEB model","volume":"136","author":"Turczynski","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib122","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jid.2026.05.023_bib123","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/sj.jid.5701152","article-title":"5' trans-splicing repair of the PLEC1 gene","volume":"128","author":"Wally","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.05.023_bib124","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","article-title":"The medicinal chemistry of therapeutic oligonucleotides","volume":"59","author":"Wan","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.jid.2026.05.023_bib125","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcag002","article-title":"Identification of siRNA silencing TGFbeta1 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma in vivo","volume":"8","author":"Wang","year":"2026","journal-title":"NAR Cancer"},{"key":"10.1016\/j.jid.2026.05.023_bib126","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2062827","article-title":"Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system","volume":"11","author":"Wei","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jid.2026.05.023_bib127","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics - challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2026.05.023_bib128","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacl.2023.03.007","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: long-term efficacy and safety data from patients in an open-label extension trial","volume":"17","author":"Witztum","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jid.2026.05.023_bib129","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jid.2026.05.023_bib130","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nbt1339","article-title":"Mechanisms and optimization of in vivo delivery of lipophilic siRNAs","volume":"25","author":"Wolfrum","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jid.2026.05.023_bib131","article-title":"New insights into microRNA in dermatological diseases","volume":"12","author":"Xu","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.jid.2026.05.023_bib132","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1016\/j.apsb.2025.09.008","article-title":"Antisense molecules: a promising new therapy for atopic dermatitis","volume":"15","author":"Xue","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.jid.2026.05.023_bib133","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1194\/jlr.M066399","article-title":"Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results","volume":"57","author":"Yang","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jid.2026.05.023_bib134","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2026.05.023_bib135","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ana.26409","article-title":"Partial Restoration of Brain dystrophin and Behavioral Deficits by Exon Skipping in the muscular dystrophy X-linked (mdx) Mouse","volume":"92","author":"Zarrouki","year":"2022","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jid.2026.05.023_bib136","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.2147\/IJN.S504639","article-title":"Using siRNA-based anti-inflammatory lipid nanoparticles for gene regulation in psoriasis","volume":"20","author":"Zeng","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.jid.2026.05.023_bib137","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41467-023-35990-7","article-title":"An integrated Mg battery-powered iontophoresis patch for efficient and controllable transdermal drug delivery","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat Commun"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26012790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26012790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:52:04Z","timestamp":1793411524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X26012790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":138,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0022202X26012790"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2026.05.023","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"History and future of RNA medicines","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2026.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}